The First Study Evaluating Effectiveness and Safety of the Endoscopic Sleeve Gastroplasty in HIV Patients.
Thiago Ferreira de SouzaAntonio C Madruga NetoMartin Andres CoronelEduardo GreccoLuiz Gustavo QuadrosMarco SilvaBarham K Abu DayyehManoel Dos Passos Galvão NetoPublished in: Obesity surgery (2021)
The authors evaluated, retrospectively, the endoscopic sleeve gastroplasty impact in seven HIV patients, regarding effectiveness and safety outcomes. The mean baseline body mass index (BMI) was 33.76 kg/m2. The mean baseline CD4+ cell count was 690.43 cells/mm3, and the baseline viral load was undetectable. After 6 months, absolute weight loss, percentage of excess weight loss, percentage total weight loss, and BMI reduction were 20.2 ± 2.6 kg, 85.5 ± 11.1%, 21.3 ± 2.4%, and 7.1 ± 0.8 kg/m2, respectively. No patients presented severe adverse events. After 6 months, the viral load remained undetectable and the mean CD4+ cell count was 710.57 cells/mm3. The endoscopic sleeve gastroplasty is an effective and safe procedure to perform in obese HIV patients.
Keyphrases
- end stage renal disease
- weight loss
- body mass index
- ejection fraction
- chronic kidney disease
- newly diagnosed
- prognostic factors
- type diabetes
- human immunodeficiency virus
- patient reported outcomes
- induced apoptosis
- physical activity
- peritoneal dialysis
- stem cells
- hiv positive
- metabolic syndrome
- ultrasound guided
- south africa
- skeletal muscle
- weight gain
- hiv aids
- gastric bypass
- endoplasmic reticulum stress
- cell therapy
- cell cycle arrest
- patient reported